Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database

Growing evidence of the possibility of modulating protein–protein interactions with small molecules is opening the door to new approaches and concepts in drug discovery. In this paper, we describe the creation of TIMBAL, a hand‐curated database holding an up to date collection of small molecules inhibiting multi‐protein complexes. This database has been analysed and profiled in terms of molecular properties. Protein–protein modulators tend to be large lipophilic molecules with few hydrogen bond features. An analysis of TIMBAL’s intersection with other structural databases, including CREDO (protein–small molecule from the PDB) and PICCOLO (protein–protein from the PDB) reveals that TIMBAL molecules tend to form mainly hydrophobic interactions with only a few hydrogen bonding contacts. With respect to potency, TIMBAL molecules are slightly less efficient than an average medicinal chemistry hit or lead. The database provides a resource that will allow further insights into the types of molecules favoured by protein interfaces and provide a background to continuing work in this area. Access at http://www‐cryst.bioc.cam.ac.uk/timbal

[1]  P. Hajduk,et al.  NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. , 1997, Journal of medicinal chemistry.

[2]  G. Powers,et al.  Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .

[3]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  N. Sigal,et al.  Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[6]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[7]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[8]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[9]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[10]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[11]  Yuzhe Xing,et al.  Small Molecule Ligands Define a Binding Site on the Immune Regulatory Protein B7.1* , 2002, The Journal of Biological Chemistry.

[12]  J. Kjems,et al.  A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A Gene-Expression Inhibitor that Targets an α-Helix-Mediated Protein Interaction , 2003 .

[14]  C. Yoakim,et al.  Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex. , 2003, Bioorganic & medicinal chemistry letters.

[15]  A gene-expression inhibitor that targets an alpha-helix-mediated protein interaction. , 2003, Journal of the American Chemical Society.

[16]  T. Berg Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.

[17]  Jing Chen,et al.  Structure-activity studies of a series of dipyrazolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1. , 2003, Bioorganic & medicinal chemistry.

[18]  J. Alvarez,et al.  Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction. , 2003, Organic & biomolecular chemistry.

[19]  Dajun Yang,et al.  Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004, Journal of medicinal chemistry.

[20]  T. Rush,et al.  Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. , 2004, Bioorganic & medicinal chemistry.

[21]  Yong Wang,et al.  Crystal Structure of the E2 Transactivation Domain of Human Papillomavirus Type 11 Bound to a Protein Interaction Inhibitor* , 2004, Journal of Biological Chemistry.

[22]  Alexander D. MacKerell,et al.  Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. , 2004, Journal of medicinal chemistry.

[23]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[24]  Michelle R Arkin,et al.  Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. , 2004, Journal of medicinal chemistry.

[25]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[26]  C. Yoakim,et al.  Characterization of the binding site for inhibitors of the HPV11 E1-E2 protein interaction on the E2 transactivation domain by photoaffinity labeling and mass spectrometry. , 2004, Analytical chemistry.

[27]  D. Coen,et al.  Identification of a small molecule that inhibits herpes simplex virus DNA Polymerase subunit interactions and viral replication. , 2004, Chemistry & biology.

[28]  K. Audouze,et al.  Emerging classes of protein-protein interaction inhibitors and new tools for their development. , 2004, Current opinion in chemical biology.

[29]  Dajun Yang,et al.  Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004 .

[30]  Saul H Rosenberg,et al.  Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.

[31]  Shaomeng Wang,et al.  Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2 , 2004, Cancer Research.

[32]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.

[33]  P. Fischer Protein-Protein Interactions in Drug Discovery , 2005 .

[34]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[35]  A. Whitty,et al.  Small-molecule inhibition of TNF-alpha. , 2005, Science.

[36]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[37]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.

[38]  J. Mekalanos,et al.  Small-Molecule Inhibitor of Vibrio cholerae Virulence and Intestinal Colonization , 2005, Science.

[39]  H. Abaan,et al.  Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.

[40]  Shufeng Zhou,et al.  Bioactivation and hepatotoxicity of nitroaromatic drugs. , 2006, Current drug metabolism.

[41]  Ramaswamy Nilakantan,et al.  Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. , 2006, Bioorganic & medicinal chemistry.

[42]  Cornel Catana,et al.  Inhibition of protein–protein interactions: The discovery of druglike β‐catenin inhibitors by combining virtual and biophysical screening , 2006, Proteins.

[43]  Dirk Eick,et al.  Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. , 2006, Chemistry & biology.

[44]  Shaomeng Wang,et al.  Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. , 2006, Bioorganic & medicinal chemistry letters.

[45]  D. Hockenbery,et al.  Small-molecule inhibitors of Bcl-2. , 2006, Current opinion in investigational drugs.

[46]  P. Fischer Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction , 2006, International Journal of Peptide Research and Therapeutics.

[47]  Holger Gohlke,et al.  Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. , 2006, Current medicinal chemistry.

[48]  Catherine L. Worth,et al.  Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[49]  Sungsam Gong,et al.  A Structural Bioinformatics Approach to the Analysis of nonsynonymous Single nucleotide polymorphisms (nsSNPS) and their Relation to Disease , 2007, J. Bioinform. Comput. Biol..

[50]  M. Åkesson,et al.  Discovery of Selective Small-Molecule CD80 Inhibitors , 2007, Journal of biomolecular screening.

[51]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[52]  Sheng Jiang,et al.  Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. , 2007, Journal of medicinal chemistry.

[53]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[54]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[55]  J. Mekalanos,et al.  Virstatin inhibits dimerization of the transcriptional activator ToxT , 2007, Proceedings of the National Academy of Sciences.

[56]  S. Gellman,et al.  Targeting protein-protein interactions: lessons from p53/MDM2. , 2007, Biopolymers.

[57]  R. Neubig,et al.  Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay , 2007, Molecular Pharmacology.

[58]  D. Fry Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. , 2008, Current protein & peptide science.

[59]  J. Nör,et al.  Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Tjelvar S. G. Olsson,et al.  The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.

[61]  T. Berg Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.

[62]  J. Walker Therapeutic Antibodies , 2009, Methods in Molecular Biology™.

[63]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[64]  Tom Blundell,et al.  CREDO: A Protein–Ligand Interaction Database for Drug Discovery , 2009, Chemical biology & drug design.